<!DOCTYPE html>
<html>
<head>
    <title>Sin&#xAD;ga&#xAD;pore to look at boost&#xAD;ing man&#xAD;u&#xAD;fac&#xAD;ture of phar&#xAD;ma&#xAD;ceu&#xAD;ti&#xAD;cal prod&#xAD;ucts - PressReader</title>
    <meta name="description" content="EDB&#x2019;s Ms Goh Wan Yee said the Repub&#xAD;lic is home to lead&#xAD;ing phar&#xAD;ma&#xAD;ceu&#xAD;ti&#xAD;cal com&#xAD;pa&#xAD;nies that man&#xAD;u&#xAD;fac&#xAD;ture a wide range of prod&#xAD;ucts, from small mol&#xAD;e&#xAD;cules and bi&#xAD;o&#xAD;log&#xAD;ics to ther&#xAD;a&#xAD;peu&#xAD;tics and vac&#xAD;cines, for the global mar&#xAD;ket.">
    <meta content="magazines, newspapers, digital news, reading, news, breaking news, newspaper online" name="keywords">
    <meta name="Robots" content="NOARCHIVE,NOODP">
    <meta charset="UTF-8">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="canonical" href="/singapore/the-straits-times/20201124/281689732362445" />


    <style>
        li {
            margin: 1em 0;
        }
        img {
            max-width: 100%;
        }
        p, h1, h2, h3 {
            max-width: 100%;
        }
    </style>
</head>
<body>
    <div>
        

<article>
    <h1>Sin&#xAD;ga&#xAD;pore to look at boost&#xAD;ing man&#xAD;u&#xAD;fac&#xAD;ture of phar&#xAD;ma&#xAD;ceu&#xAD;ti&#xAD;cal prod&#xAD;ucts</h1>
    <h2></h2>
    <section>
        <a href="/singapore/the-straits-times/textview" title="The Straits Times">The Straits Times</a>
        - <a href="/singapore/the-straits-times/20201124/textview" title="The Straits Times - 2020-11-24"><time>2020-11-24</time></a>
        - <span>THE BIG STORY</span>
        - <span role="byline">Au&#xAD;drey Tan</span>
    </section>

    <p>EDB’s Ms Goh Wan Yee said the Repub­lic is home to lead­ing phar­ma­ceu­ti­cal com­pa­nies that man­u­fac­ture a wide range of prod­ucts, from small mol­e­cules and bi­o­log­ics to ther­a­peu­tics and vac­cines, for the global mar­ket.</p>
    <p>Plans are afoot to ex­pand Sin­ga­pore’s ca­pac­ity in the man­u­fac­ture of phar­ma­ceu­ti­cal prod­ucts as the world gets closer to find­ing a vac­cine for Covid-19.</p>
    <p>Global life-science com­pany Thermo Fisher Sci­en­tific, for in­stance, last month an­nounced plans to set up a ster­ile fill-andfin­ish fa­cil­ity for ther­a­peu­tics and vac­cines here.</p>
    <p>“This fa­cil­ity will have the ca­pa­bil­ity and ca­pac­ity to ad­dress the de­mand in the re­gion, and also en­hance Sin­ga­pore’s abil­ity to re­spond to fu­ture pan­demics,” said Ms Goh Wan Yee, se­nior vi­cepres­i­dent and head for health­care at the Eco­nomic De­vel­op­ment Board (EDB).</p>
    <p>In June, Prime Min­is­ter Lee Hsien Loong said Sin­ga­pore in­tends to of­fer fill-and-fin­ish con­tract man­u­fac­tur­ing ser­vices to vac­cine de­vel­op­ers.</p>
    <p>Fill-and-fin­ish man­u­fac­tur­ing in­volves con­tam­i­na­tion-free fill­ing of drugs into con­tain­ers such as vials or sy­ringes.</p>
    <p>It plays a crit­i­cal role in scal­ing up vac­cine pro­duc­tion for pop­u­la­tions as many bio­phar­ma­ceu­ti­cal prod­ucts are frag­ile and prone to con­tam­i­na­tion.</p>
    <p>Ms Goh said that vac­cine man­u­fac­tur­ing is not new to Sin­ga­pore as it is sim­i­lar to bi­o­log­ics man­u­fac­tur­ing.</p>
    <p>Bri­tish phar­ma­ceu­ti­cal gi­ant Glax­oSmithK­line (GSK), for ex­am­ple, has a vac­cines drug sub­stance man­u­fac­tur­ing plant in Tuas that has been op­er­a­tional since 2011, she added.</p>
    <p>GSK cur­rently has three Covid-19 vac­cine col­lab­o­ra­tions in clin­i­cal tri­als world­wide, and a spokesman for the firm told The Straits Times that all three are ex­pected to go into late-stage hu­man tri­als by the year end.</p>
    <p>She added that more than one vac­cine would likely be needed to tackle the pan­demic, and said the firm was hop­ing that there would be a num­ber of suc­cess­ful vac­cines de­vel­oped with GSK’s pan­demic ad­ju­vant tech­nol­ogy. Ad­ju­vants are an in­gre­di­ent used to boost the hu­man im­mune re­sponse.</p>
    <p>GSK’s plant in Tuas pro­duces a dif­fer­ent in­gre­di­ent – con­ju­gates – for its pneu­mo­coc­cal con­ju­gate vac­cines.</p>
    <p>The man­u­fac­ture and fill-andfin­ish ad­ju­vant pro­duc­tion for use in Covid-19 vac­cines will be done at sites in Bri­tain, the United States, Canada and Europe, said the GSK spokesman.</p>
    <p>But GSK is still a ma­jor con­trib­u­tor to Sin­ga­pore’s biomed­i­cal sci­ences in­dus­try, with more than $1.5 bil­lion in in­vest­ments.</p>
    <p>For in­stance, other than its vac­cine man­u­fac­tur­ing fa­cil­ity, it has two global man­u­fac­tur­ing sup­ply sites in Sin­ga­pore.</p>
    <p>EDB’s Ms Goh said the Repub­lic is home to lead­ing phar­ma­ceu­ti­cal com­pa­nies that man­u­fac­ture a wide range of prod­ucts, from small mol­e­cules and bi­o­log­ics to ther­a­peu­tics and vac­cines, for the global mar­ket.</p>
    <p>“These com­pa­nies have cho­sen to set up strate­gic pro­duc­tion sites here to lever­age Sin­ga­pore’s base of skilled ta­lent, global con­nec­tiv­ity and tech­no­log­i­cal ca­pa­bil­i­ties,” she added.</p>
    <p>Last year, Sin­ga­pore’s phar­ma­ceu­ti­cal man­u­fac­tur­ing in­dus­try ac­counted for $21.9 bil­lion in to­tal out­put and em­ployed about 8,600 work­ers.</p>
    <p>“EDB will con­tinue to grow the bio­phar­ma­ceu­ti­cal man­u­fac­tur­ing sec­tor to un­der­take ac­tiv­i­ties in new tech­nolo­gies and modal­i­ties as part of larger ef­forts to fur­ther di­ver­sify Sin­ga­pore’s man­u­fac­tur­ing base,” she added.</p>

    <div>
        <picture>
            <img src="https://i.prcdn.co/img?regionKey=%2bipeYrJt9Bt2GnFfIFWSGA%3d%3d" />
        </picture>
        <span role="byline">PHOTO: GLAX&#xAD;OSMITHK&#xAD;LINE</span>
        <p data-role="text">Glax&#xAD;oSmithK&#xAD;line&#x2019;s vac&#xAD;cine man&#xAD;u&#xAD;fac&#xAD;tur&#xAD;ing plant in Tuas. The phar&#xAD;ma&#xAD;ceu&#xAD;ti&#xAD;cal gi&#xAD;ant has three Covid-19 vac&#xAD;cine col&#xAD;lab&#xAD;o&#xAD;ra&#xAD;tions in clin&#xAD;i&#xAD;cal tri&#xAD;als world&#xAD;wide, and all three are ex&#xAD;pected to go into late-stage hu&#xAD;man tri&#xAD;als by the year end, said a spokesman.</p>
    </div>

</article>

<section>
    <h3><a href="/catalog/language/english">Newspapers in English</a></h3>
    <h3><a href="/catalog/country/singapore">Newspapers from Singapore</a></h3>
</section>

    </div>
    
    <p><a href="http://www.pressreader.com">© PressReader. All rights reserved.</a></p>

        <script>
            (function (i, s, o, g, r, a, m) {
                i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () {
                    (i[r].q = i[r].q || []).push(arguments);
                }, i[r].l = 1 * new Date();
                a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g;
                m.parentNode.insertBefore(a, m);
            })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
        </script>
        <script>
            ga('create', 'UA-44408245-1');
            ga('send', 'pageView');
        </script>
</body>
</html>
